BR112020020868A2 - Anticorpos de galectina-10 - Google Patents

Anticorpos de galectina-10 Download PDF

Info

Publication number
BR112020020868A2
BR112020020868A2 BR112020020868-0A BR112020020868A BR112020020868A2 BR 112020020868 A2 BR112020020868 A2 BR 112020020868A2 BR 112020020868 A BR112020020868 A BR 112020020868A BR 112020020868 A2 BR112020020868 A2 BR 112020020868A2
Authority
BR
Brazil
Prior art keywords
seq
amino acid
acid sequence
galectin
antibody
Prior art date
Application number
BR112020020868-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Bart LAMBRECHT
Emma PERSSON
Savvas Savvides
Hamida Hammad
Kenneth Verstraete
Jean-Michel PERCIER
Christophe Blanchetot
Michael Saunders
Hans De Haard
Bas Van Der Woning
Original Assignee
Argenx Bvba
Vib Vzw
Universiteit Gent
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1806099.6A external-priority patent/GB201806099D0/en
Priority claimed from GBGB1901648.4A external-priority patent/GB201901648D0/en
Application filed by Argenx Bvba, Vib Vzw, Universiteit Gent filed Critical Argenx Bvba
Publication of BR112020020868A2 publication Critical patent/BR112020020868A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4724—Lectins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112020020868-0A 2018-04-13 2019-04-12 Anticorpos de galectina-10 BR112020020868A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1806099.6A GB201806099D0 (en) 2018-04-13 2018-04-13 Galectin-10 Antibodies
GB1806099.6 2018-04-13
GBGB1901648.4A GB201901648D0 (en) 2019-02-06 2019-02-06 Galectin-10 antibodies
GB1901648.4 2019-02-06
PCT/EP2019/059570 WO2019197675A1 (en) 2018-04-13 2019-04-12 Galectin-10 antibodies

Publications (1)

Publication Number Publication Date
BR112020020868A2 true BR112020020868A2 (pt) 2021-04-06

Family

ID=66240109

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020020868-0A BR112020020868A2 (pt) 2018-04-13 2019-04-12 Anticorpos de galectina-10

Country Status (12)

Country Link
US (3) US11066473B2 (https=)
EP (1) EP3774905A1 (https=)
JP (1) JP2021520825A (https=)
KR (1) KR20210005070A (https=)
CN (1) CN112166126A (https=)
AU (1) AU2019250689A1 (https=)
BR (1) BR112020020868A2 (https=)
CA (1) CA3094215A1 (https=)
IL (1) IL278010A (https=)
MX (1) MX2020010821A (https=)
SG (1) SG11202009140SA (https=)
WO (1) WO2019197675A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020010821A (es) 2018-04-13 2021-01-15 Argenx Iip Bv Anticuerpos contra galectina-10.
US11860114B2 (en) * 2020-03-26 2024-01-02 David Hurwitz Determining atomic coordinates from X-ray diffraction data
WO2021223079A1 (zh) * 2020-05-06 2021-11-11 科稷达隆(北京)生物技术有限公司 一种纳米抗体及其应用
CN113666999B (zh) * 2021-08-31 2022-08-19 中国医学科学院基础医学研究所 用于治疗2型免疫疾病的多肽
CN113667000B (zh) * 2021-08-31 2022-08-19 中国医学科学院基础医学研究所 多肽在制备治疗2型免疫疾病的药物中的应用
CN113999287B (zh) * 2021-12-02 2023-06-27 深圳湾实验室坪山生物医药研发转化中心 一种靶向半乳糖凝集素-10的多肽抑制剂及其制备方法和用途
IL314367A (en) 2022-01-18 2024-09-01 argenx BV Antibodies to galectin 10
KR20240133723A (ko) 2022-01-18 2024-09-04 아르제넥스 비브이 Fab 단편의 분무화
WO2023150260A2 (en) * 2022-02-03 2023-08-10 Regents Of The University Of Minnesota Compounds that target tem8, compositions, and methods
JPWO2023153496A1 (https=) * 2022-02-10 2023-08-17
CN115785245A (zh) * 2022-07-18 2023-03-14 上海博满生物科技有限公司 一种半乳糖凝集素10晶体及其制备的抗体IgY和药物制剂
CN115902204A (zh) * 2022-09-23 2023-04-04 北京大学第三医院（北京大学第三临床医学院） 一种外泌体形式半乳糖凝集素9的检测方法与试剂盒
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
DE10333406A1 (de) * 2003-07-15 2005-02-10 Protagen Ag T-regulatorische-Zellen enthaltend Galectine zur Therapie und Diagnose von Erkrankungen
GB2461546B (en) 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
CA2988388C (en) * 2015-04-23 2022-11-22 Nantomics, Llc Cancer neoepitopes
CN106645752B (zh) * 2016-12-27 2018-02-16 中南大学湘雅医院 Galectin‑10及其特异性抗体在制备检测鼻咽癌试剂盒中的应用
MX2020010821A (es) 2018-04-13 2021-01-15 Argenx Iip Bv Anticuerpos contra galectina-10.

Also Published As

Publication number Publication date
SG11202009140SA (en) 2020-10-29
EP3774905A1 (en) 2021-02-17
JP2021520825A (ja) 2021-08-26
WO2019197675A1 (en) 2019-10-17
CA3094215A1 (en) 2019-10-17
MX2020010821A (es) 2021-01-15
US11713354B2 (en) 2023-08-01
US20240026010A1 (en) 2024-01-25
CN112166126A (zh) 2021-01-01
US11066473B2 (en) 2021-07-20
KR20210005070A (ko) 2021-01-13
US20190367619A1 (en) 2019-12-05
US20210332140A1 (en) 2021-10-28
AU2019250689A1 (en) 2020-10-08
IL278010A (en) 2020-11-30

Similar Documents

Publication Publication Date Title
US20240026010A1 (en) Galectin-10 antibodies
US11242404B2 (en) Antibodies against signal-regulatory protein alpha and methods of use
AU2020250266C1 (en) Antibodies comprising an ion concentration dependent antigenbinding domain, fc region variants, il-8-binding antibodies, and uses thereof
JP6345800B2 (ja) 抗体−フィノマー複合体
US20200079863A1 (en) Antibodies that bind to tl1a and their uses
US9845363B2 (en) Antibodies to plasminogen activator inhibitor-1 (PAI-1) and uses thereof
JP2025087672A (ja) 抗ｋｌｋ７抗体、抗ｋｌｋ５抗体、多重特異性抗ｋｌｋ５／ｋｌｋ７抗体および使用方法
TW201819417A (zh) 結合至凝血因子ix及凝血因子x之雙特異性抗體
BR112013016235B1 (pt) Anticorpo isolado, uso de um anticorpo, ácido nucleico, célula transformada e composição farmacêutica
TW201302794A (zh) 人類組織因子抗體及其用途
ES2903412T3 (es) Anticuerpos anti-IL-22R
KR20240049265A (ko) 인간 피브린 또는 피브리노겐 γC 도메인에 결합하는 항체 및 사용 방법
CN115697393A (zh) 抗PHF-tau抗体及其用途
TW202328208A (zh) 抗ｔｒｏｐ－２抗體或其抗原結合片段、產生其的方法及其用途
TW202509068A (zh) 結合ox40l之抗體及使用方法
TW202444762A (zh) 自體免疫性疾病的治療
JP2024515643A (ja) 抗ヒトｍａｓｐ－２抗体、並びにその製造法及び使用
CN118488967A (zh) 半乳凝素-10抗体
HK40034251A (en) Galectin-10 antibodies
EA047651B1 (ru) Антитела против галектина-10
JP2017057201A (ja) 抗体−フィノマー複合体を含む医薬組成物
TW202523697A (zh) 抗ｔｓｌｐ抗體構築體及其用途
EA046142B1 (ru) Антитела к trem-1 и их применения
TW201335184A (zh) 人類組織因子抗體及其用途

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: VIB VZW (BE) ; UNIVERSITEIT GENT (BE) ; ARGENX IIP BV (BE)

B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]
B25F Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement

Owner name: VIB VZW (BE) ; UNIVERSITEIT GENT (BE) ; ARGENX IIP BV (BE)

Free format text: A FIM DE ATENDER A ALTERACAO DE NOME REQUERIDA ATRAVES DA PETICAO 870230044010 DE 25/05/2023, E NECESSARIO ESCLARECER A DIVERGENCIA ENTRE O NOME DO DEPOSITANTE CONSTANTE NOS DOCUMENTOS APRESENTADOS ?ARGENX BENELUX? E O CONSTANTE NO FORMULARIO ?ARGENX BENELUX BV?.

B25D Requested change of name of applicant approved

Owner name: VIB VZW (BE) ; UNIVERSITEIT GENT (BE) ; ARGENX BENELUX BV (BE)

B25A Requested transfer of rights approved

Owner name: VIB VZW (BE) ; UNIVERSITEIT GENT (BE) ; ARGENX BV (BE)